Asymptomatic carriage of *Plasmodium falciparum* in children living in a hyperendemic area occurs independently of IgG responses but is associated with a balanced inflammatory cytokine ratio.

Balotin Fogang[1,2], Matthieu Schoenhals[1], Franklin M. Maloba[1], Marie Florence Biabi[1,3], Estelle Essangui[1], Christiane Donkeu[1,2], Glwadys Cheteug[1,4], Marie Kapen[1], Rodrigue Keumoe[1], Sylvie Kemleu[1], Sandrine Nsango[1,5], Douglas H. Cornwall[6], Carole Eboumbou[1,5], Ronald Perraut[1], Rosette Megnekou[2], Tracey J. Lamb*[6] and Lawrence S. Ayong*[1]

Affiliations:

[1] Molecular Parasitology Laboratory, Centre Pasteur du Cameroun, BP 1274 Yaounde, Cameroon

[2] Department of Animal Biology and Physiology of the University of Yaoundé I, BP 812 Yaounde, Cameroon

[3] Department of Biochemistry, University of Douala, BP 24157 Douala, Cameroon

[4] Department of Medical Laboratory Sciences, University of Buea, BP 63 Buea, Cameroon

[5]Faculty of Medicine and Pharmaceutical Sciences, University of Douala, BP 2701 Douala, Cameroon

[6] Department of Pathology, University of Utah, 15 N Medical Drive, Salt Lake City 84112, USA

* Co-corresponding authors

Correspondence to: Tracey Lamb tracey.lamb@path.utah.edu Tel: +1 801 213 2097

19 **Footnote Page**

20 All authors declare no conflict of interest in this study. This work was supported by a capacity
21 building grant from the Institute Pasteur International Division to LSA. This information has
22 previously been presented at the American Association for Tropical Medicine and Hygiene Annual
23 Meeting in 2019. Correspondence to: Tracey Lamb tracey.lamb@path.utah.edu

Abstract

Background: Asymptomatic carriage of infected red blood cells (iRBCs) can be prevalent in communities regardless of transmission patterns and can occur with infection of different *Plasmodium* species. Clinical immunity dampens the inflammatory responses leading to disease symptoms in malaria. The aim of this study was to define the immunological correlates of asymptomatic carriage of *P. falciparum* in a highly exposed population.

Methods: 142 asymptomatic *Plasmodium*-infected individuals greater than 2 years of age without fever (body temperature <37.5°C) were followed weekly for 10 weeks before being treated with artemisinin-based combination treatment (ACT). Plasma levels of 38 cytokines were measured at baseline by Luminex and the quantity and growth inhibitory activities of circulating parasite-reactive antibodies measured. The *Plasmodium* antigen tested included *P. falciparum* merozoite extract (ME) and schizont extract (SE), and the recombinant proteins Erythrocyte binding antigen 175 (EBA-175) and merozoite surface protein 1 (MSP-1_{19}).

Results: Median levels of IgG against *P. falciparum* EBA-175 and MSP-1_{19} at baseline were significantly higher in those older than 20 years of age compared with the younger age group and appeared to correlate with better parasite control. Amongst all participants there were no discernible changes in IgG levels over time. Parasite density was higher in the younger age group and associated with IL-10, TNF-α and MCP-1 levels. A balanced IL-10:TNF-α ratio was associated with asymptomatic malaria regardless of age, and balanced ratios of IL-10/TNF-α and IL-10/IFN-γ were the only significant correlate of maintenance of asymptomatic malaria over the course of the study in individuals 20 years of age and younger.

Conclusion: The above findings indicate that asymptomatic carriage of *P. falciparum* in children living in a hyperendemic area occurs independently of IgG but is associated with a balanced inflammatory cytokine ratio.

Key words: Asymptomatic malaria, *Plasmodium falciparum*, IgG and cytokine levels, TNF-α, IL-10

Introduction

Malaria is still a significant global health problem with an estimated 249 million cases and 608 000 deaths in 2022 [1]. Although mortality rates from malaria have decreased considerably since the turn of the century [2] this has been paralleled by high increases in proportions of asymptomatic infections, known to contribute significantly to persistent malaria transmission in most endemic countries [3,4]. Asymptomatic infections can persist for weeks to years [5] and untreated *P. falciparum* infections have been shown persist on average for 6 months, with fluctuations in parasite density over the course of an infection [6,7]. The maintenance of chronic asymptomatic malaria will depend on the host immune response to the blood stage of *Plasmodium* [3]. Anti-parasite immunity directly suppress parasite growth resulting in low infection densities (below the pyrogenic threshold [3,8]) whilst anti-disease immunity modulates inflammation-mediated clinical manifestations of the infection.

Older children and adults have more cumulative exposure to parasite variants circulating within the community, developing adaptive responses which mediate both anti-parasite and anti-disease immunity [9,10]. However, asymptomatic infections have been documented in younger children < 5 years who are too young to have developed robust adaptive immunity [11]. This suggests that asymptomatic malaria may be differentially controlled by innate and adaptive immune responses depending on age.

Anti-parasite immunity which is acquired with age or exposure [12,13], is mediated mainly by antibodies which control parasite replication and mediate clearance of *Plasmodium*-infected red blood cells (iRBCs) [14–16]. Suppression of inflammation associated with iRBCs depends on the balance between anti- and pro-inflammatory cytokine responses [17,18] and it has been hypothesized that asymptomatic infections are associated with a shift in host immune responses towards an anti-inflammatory profile after multiple exposures to malaria [19]. This could occur via a decrease in

levels of pro-inflammatory immune mediators such as IFN-γ, TNF-α, or an increase in anti-inflammatory mediators such as IL-10 or TGF-β [18,20–22].

The relative contributions of anti-parasite and anti-disease immunity to the maintenance of persistent asymptomatic *Plasmodium* infections in younger individuals and older individuals remain unclear. To determine the immunological associations of chronic asymptomatic malaria in younger (≤20 years) and older (>20 years) individuals we have undertaken a longitudinal study of highly exposed individuals of all ages with asymptomatic malaria over a 3-month period where we monitored the stability of IgG and cytokine responses. We also examined these responses upon clearance of parasites to ascertain which responses depended on the presence of circulating parasites. Our study demonstrates a lack of correlation of iRBC density and IgG responses in individuals ≤20 years old, with an association of parasite carriage with IL-10 and an association of asymptomatic status with a balanced ratio of IL-10:TNF-α and IL-10: IFN-γ.

Material and methods

Ethics statement

The study protocol was approved by the Cameroon National Ethics Committee for Human Health Research (Ethical clearance N°: 2018/09/1104/CE/CNERSH/SP) and the Ministry of Public Health. Written informed consent was obtained from each participant or parent/guardian of minor participants (< 19 years old) prior to enrolment into the study. Assent was obtained from all children older than 12 years of age.

Study area and population

The study population consisted of individuals of both genders aged at least two years of age and permanently living in one of the five selected villages of the Esse health district, Mefou-et-Afamba Division, Centre Region of Cameroon where malaria transmission is perennial, stable and hyper-endemic with *P. falciparum* as the predominant *Plasmodium* species. The study area has been

98 described elsewhere [23–25]. The inclusion criteria were: i) obtain the consent of each older
99 participant or parent or legal guardian for the children, ii) living permanently in the study area, iii)
100 not pregnant.

101 **Study design and participants**

102 This was a longitudinal household-based study that involved 353 individuals. Participants were
103 considered asymptomatic for malaria if positive for *P. falciparum* using multiplex nested PCR in the
104 absence of fever at least forty-eight hours prior to enrolment. Being febrile was assessed based on
105 axillary temperature ≥ 37.5 °C or based on the history of fever as independently confirmed by another
106 household member. All symptomatic individuals (fever + rapid diagnostic test (RDT) +) were treated
107 with ACT-based drugs following recommended national guidelines. Participants with asymptomatic
108 carriage of *Plasmodium* parasites were monitored weekly until they either developed a fever, or until
109 the end of the follow up period at week 16 post-enrolment. Participant follow-up comprised of weekly
110 interviews regarding the occurrence of fever during the past week, measurement of axillary
111 temperatures on each visit, and laboratory testing for malaria at weeks 1, 4, 11 and 16 (PCR and
112 microscopy). All symptomatic cases occurring during the follow-up period were treated with ACT as
113 recommended and excluded from further follow-up. At week 11 post-enrolment all participants with
114 persisting asymptomatic parasitemia were treated as recommended, and monitored for five additional
115 weeks to assess the effect of ACT-based antimalarial treatment on selected host immune responses.
116 Participants with persistent asymptomatic parasitemia 10 weeks following enrolment were
117 considered as persistent asymptomatic malaria whereas those who developed malaria-associated
118 symptoms before week 11 post-enrolment were considered as developing uncomplicated malaria.

119 **Blood sample collection, malaria diagnosis and parasite genotyping**

120 Approximately 3 ml of venous blood was collected in EDTA-coated tubes and used for laboratory
121 testing for malaria and blood hemoglobin levels as well as to obtain plasma for immunological
122 analysis. Plasma was separated from the red blood cell (RBC) pellet by centrifugation (3500 RPM,

123 5 min) and stored at -80 °C until use. Blood hemoglobin levels were assessed using a portable Mission
124 Hb haemoglobinometer (ACON Laboratories, USA).

125 Parasite density (parasites/µl) was determined by microscopic examination of Giemsa-stained thick
126 blood smears. Parasite density was determined based on the number of parasites per at least 200 WBC
127 count on a thick film, assuming a total white blood cell count of 8000 cells/µL of whole blood. A
128 blood slide was considered positive when a concordant result was obtained by at least two
129 independent microscopists and when a discrepancy occurred, a third microscopist was used for
130 confirmation. A slide was considered negative if no parasites were detected after a count of 500 white
131 blood cells.

132 Genomic DNA was extracted from dried blood spots using the Chelex method [26], and used to
133 screen for *Plasmodium* infections by multiplex nested PCR targeting the 18S small subunit rRNA
134 (ssrRNA) genes as previously described [24]. Genotyping of *msp2* gene was performed by nested
135 PCR on *P. falciparum* PCR positive samples as previously described [24,27].

136 **Case definitions for the study**

137 Participants were defined as asymptomatic if positive for malaria parasites by PCR in the absence of
138 fever at least 48 hours prior to enrolment. Febrile malaria was determined based on RDT, light
139 microscopy or PCR positivity for malaria parasites and axillary temperature ≥ 37.5°C or a history of
140 fever in the past 48 hours. Those developing uncomplicated malaria were defined as asymptomatic
141 individuals who had developed fever associated with *Plasmodium* infection during the 10-week
142 infection follow-up period, whereas the persistent asymptomatic malaria classification represented
143 the asymptomatic individuals who remained asymptomatic until anti-malarial treatment at the end of
144 the infection follow-up period.

145 **Anti-*Plasmodium* antibody levels and avidity assessment**

146 Plasma IgG antibody levels and avidity were determined by indirect ELISA method using *P.*
147 *falciparum* Merozoite extract (ME), schizont extract (SE) or the recombinant proteins erythrocyte
148 binding antigen-175 (EBA-175) and Merozoite Surface Protein-1_{19} (MSP1_{19}) as coating antigens.
149 ME and SE were isolated from laboratory maintained *P. falciparum* 3D7 parasites as described
150 previously [28], and used for protein extraction by freeze-thaw fractionation [23,29]. The
151 recombinant protein EBA-175 (F3 region) was obtained from BEI Resources (MRA-1162), whereas
152 *P. falciparum* MSP1_{19} was produced using a baculovirus-insect cell expression system [30].
153
154 96-well microplates (F96 CERT-Maxisorp) were coated with each antigen (2 mg/ml of ME and SE,
155 0.20 mg/ml of EBA-175 and 0.5 mg/ml of MSP-1_{19}) in 0.1 M bicarbonate buffer (for ME, SE and
156 EBA-175) or PBS (for MSP-1_{19}) and incubated overnight at 4˚C. Plasma samples were diluted
157 (1/250) in PBS-T/1%BSA and used to measure anti-*Plasmodium* IgG as previously described [23,31].
158 Plasma from non-exposed European blood donors (10 samples) were used as naive controls and a
159 pool of IgG fractions from adults living in high malaria endemic areas was used as positive controls.
160 Results were expressed as optical-density ratios (OD sample/mean OD naive control). For avidity
161 testing, 100 µL of 8M urea in wash buffer (treated wells) or 100 µL of wash buffer (untreated wells)
162 were added for 15 minutes at room temperature to the respective wells following primary antibody
163 binding as previously described [32]. Avidity indices (AI) were calculated as proportion of bound
164 antibodies following urea treatment (AI = [mean OD of treated wells /mean OD of untreated wells]
165 × 100). Samples with OD ratios > 2, corresponding to mean OD naive control + 3SD were considered
166 as seropositive. In addition, only seropositive samples were used for avidity testing.
167

168 **Growth inhibition assay (GIA)**

169 GIA was performed using plasma from endemic and non-endemic individuals as described by
170 Duncan *et al.* [33]. Briefly, plasma samples were heat inactivated at 56 ° C for 20 min and a 1:20

171 ratio of 50% RBC was added to each sample and incubated at room temperature for 1 h to remove
172 the RBC-reactive antibody. After spinning for 2 min at 13,000 x *g* to pellet the RBCs, the
173 supernatant was transferred to a 96-well V-bottom plate. Synchronized late trophozoite/early
174 schizont (30-40 h) stages of 3D7 *P. falciparum* at 0.5% parasitemia were incubated with plasma
175 (1:10 ratio) for 48 h at 37 °C. The GIA harvest (parasite growth) was carried out by SYBR green-I
176 DNA quantification assay [34]. Parasite growth inhibition (GI) activities of plasma antibodies were
177 presented as: GI indices (%) = 100 x [1 - ((OD sample - OD RBC) / (OD parasitized RBC - OD
178 RBC))].

179 **Determination of plasma cytokine levels**

180 Plasma concentrations of 38 immune mediators including interleukin (IL)-1α, IL-1β, IL-1RA, IL-2
181 IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-p70, IL-13, IL-15, IL-17A, interferon
182 (IFN)-α2, IFN-γ, tumor necrosis factor (TNF)-α, lymphotoxin-α (LT-α), IFN-γ induced protein (IP-
183 10), monocyte chemoattractant protein (MCP)-1, MCP-3, macrophage inflammatory protein (MIP)-
184 1α, MIP-1β, Eotaxin, Fractalkine, human growth-regulated oncogene (GRO), Macrophage-derived
185 chemokine (MDC), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte
186 colony-stimulating factor (G-CSF), sCD40L, FMS-like tyrosine kinase 3 ligand (Flt-3L), epidermal
187 growth factor (EGF), fibroblast growth factor 2 (FGF-2), transforming growth factor alpha (TGF-α)
188 and vascular endothelial growth factor (VEGF) were determined by Luminex-based method using
189 the Human Cytokine/Chemokine Magnetic Bead Panel MILLIPLEX MAP Kit (Cat. No.
190 HCYTMAG-60K-PX38, EMD Millipore Corporation) according to the manufacturer's instructions.
191 Briefly, 25 µL of premixed magnetic capture beads were incubated with equal volumes of plasma or
192 diluted standard in a 96-well microplate placed on a horizontal plate shaker for 2 hours. After washing
193 using a magnetic plate, plates were incubated with 25 µL/well of biotinylated detection antibodies
194 for 1 hour at room temperature followed by 25 µL of streptavidin-PE in each well for 30 minutes at
195 room temperature. Median fluorescence intensity was read on a Luminex MAGPIX Analyser (XMAP
196 Technology) equipped with xPONENT software version 4.2. The relative concentration of each

197 cytokine (pg/ml) in each sample was determined based on the automatically generated standard curve
198 for each analyte. Analyte amounts less than the limit of detection for each cytokine were attributed
199 the value of detection limit.

200 **Statistical analysis**

201 Statistical analyses were performed using RStudio version 4.1.1 or version 4.2.2 [35] and Graphpad
202 Prism version 8.4.3 (Graphpad software, San Diego, California USA). Differences in antibody and
203 cytokine distribution between two or more groups were determined using Wilcoxon signed rank test
204 and Kruskal-Wallis test, respectively. Spearman rank correlation tests or linear regression were
205 used to determine the correlation between quantitative variables. Differences in categorical
206 variables were determined by chi-square tests. P-values < 0.05 were considered statistically
207 significant. Factor analysis of mixed data (FAMD) with FactoMineR and factoextra packages was
208 used to assess the association between cytokines levels and age and circulating parasite loads. The
209 complexHeatmap and ggpubr packages were used to draw the heatmaps and the line plots,
210 respectively. Given that the aim of this study was to determine the host immunological
211 determinants in the maintenance of the asymptomatic infections, among the 353 individuals
212 included, only participants with complete information on the study outcome during the longitudinal
213 follow-up period were included in the analysis (n= 211). Participants who missed at least one of the
214 follow-up points (the predominant reason being farming far away from the enrolment site) were not
215 included in our study. Three samples (2 symptomatic and 1 asymptomatic) were excluded because
216 no cytokines were detected in the plasma. For analysis of cytokines at the initial time point of our
217 study with respect to correlation with persistent asymptomatic malaria, we employed a mixed linear
218 model using the LME4 package [36]. Cytokine level was used as the response with conversion
219 status as the fixed-effect of the model. We used sex and age as random effects in the model and ran
220 the model separately for children ≤20 years old, adults >20 years old and all participants, regardless
221 of age. To obtain p-value estimates from the t-values we used the lmerTest package [37]. P values
222 were corrected for multiple comparisons using the Sattherthwaite correction. For analysis, parasite

223 densities were separated into three groups as follows, 1. submicroscopic parasitemia, 2. low levels
224 of microscopic parasitemia (parasitemia between 37.2 parasites/µl and 413.1 parasites/µl) and 3.
225 high levels of parasitemia (parasitemia> 413.1 parasites/µl, representing the median parasitemia in
226 the study population).
227

228 **Results**

229 **Asymptomatic malaria prevalence in the study area**

230 We carried out immunological analysis of a subset of 211 individuals from a previously reported
231 study of 353 individuals screened for malaria using PCR, where 328 (92.9%) were positive for
232 *Plasmodium falciparum* infection, of which 266 (81.1%) were asymptomatic and 62 (18.9%) were
233 symptomatic [24]. This subset had complete sampling from the follow-up study, and included 142
234 individuals with asymptomatic infection, 61 symptomatic individuals and 8 non-infected individuals.
235 At baseline when these individuals were first sampled, parasite densities were highly variable
236 between the symptomatic and asymptomatic groups, and no significant difference was observed in
237 the median parasite densities of the two groups at the initial time point of the study (**Table 1**). Age,
238 sex, and hemoglobin levels were also not different across the study groups at this initial time point
239 (**Table 1**).
240

Variables	Non detectable infection (n= 8)		Asymptomatic (n= 142)		Symptomatic (n= 61)		P value	
Age groups	**≤ 20**	**> 20**	**≤ 20**	**> 20**	**≤ 20**	**> 20**	**≤ 20**	**> 20**
n	**5**	3	**94**	48	**42**	19		
Sex ratio (M:F)	0.67 (2:3)	50 (1:2)	0.82 (42:51)	41.2 (14:34)	1.1 (22:20)	58.3 (7:12)	0.7114	0.8280
Median age, years (range)	14 (4-20)	68 (50-68)	9 (2–19)	50 (22-86)	9 (2–20)	28 (21-64)	0.2193	0.0028
Median Hb, g/dl (range)	11.8 (10.7-12.7)	112.5 (11.9-14)	12 (4.9-14.3)	13.1(10.9-16)	11.1 (6.8-14)	12.8 (9.4-16.8)	0.1866	0.9833
% of submicroscopic % (n)	-		22.3 (21)	60.4 (29)	9.5 (4)	57.9 (11)	0.0746	0.8495
Geometric mean parasitemia, parasites/µl (range)	-		575.7 (37.4-68190.5)	113.5 (38.3-660.2)	764.1 (38.1-240457.1)	183.3(37.2-5058.8)	0.5139	0.6101

Table 1. Characteristics of the study population

The data presented in this table is from 211 individuals from our study at baseline. The subset of 142 asymptomatic individuals included in this table were those individuals with complete data from the follow-up study to 11 weeks and does not include baseline data from individuals who dropped out of the study. P-value was determined using Wilcoxon signed-rank test and Kruskal-Wallis test when comparing two or three groups, respectively. The median parasitemia presented in this table is only for the infected individuals with parasite densities at the detection limit of light microscopy. The sex ratio between groups were compared using chi-square test. Hb: hemoglobin. M: male. F: female.

245

246 **Anti-parasite antibodies were inversely correlated with parasitemia but were not associated**
247 **with asymptomatic parasite carriage**

248 Consistent with the hypothesis that host immunity increases with repeated exposure to malaria
249 parasites, baseline parasite densities above the detection limit of microscopy decreased significantly
250 with age (r= -0.49, P< 0.0001) **(Figure 1A)** but only in individuals aged 20 years and younger (r= -
251 0.39, P< 0.0001) (**Figure 1B**). Of the 142 participants who completed the follow-up study as
252 designed, 78 (54.9%) remained asymptomatic during the 10-weeks follow-up period, whereas 63
253 (44.4%) developed malaria-associated fevers and 1 (0.7%) resolved the infection in the absence of
254 any known antimalarial treatment. Based on the parasitemia distribution of those with microscopic
255 *Plasmodium* infections at baseline the study population was divided into two groups aged ≤ 20 years
256 and > 20 years old for further analyses. The proportion of submicroscopic infections was significantly
257 higher (P<0.0001) in the older age group (age >20 years) at the baseline time point than in the younger
258 age group (**Figure 1C**). At the baseline time point, median IgG levels against *P. falciparum* merozoite
259 (ME) and schizont (SE) crude extracts were significantly higher in the >20-year age group than in
260 the younger age group (P< 0.0001) (**Figure 2A**). This was mirrored by IgG reactive to *P. falciparum*
261 recombinant proteins EBA-175 (P= 0.0250) and MSP-1_{19} (P< 0.0001) (**Figure 2A**). Additionally, In
262 the younger age group IgG levels against merozoite (r= 0.22, P= 0.0077) and schizont (r= 0.29, P=
263 0.0004) crude extracts as well as against MSP-1_{19} (r= 0.15, P= 0.0764) but not EBA-175 (r= 0.01, P=
264 0.8525) were positively correlated with age at the baseline time point (**Figure 2B**). A negative
265 correlation was observed between IgG levels to *P. falciparum* merozoite and schizont extracts at
266 baseline and parasite density measured at the same time point (**Supplementary Figure 1**). Indeed,
267 the multilevel linear regression model adjusted for village and household levels, using IgG levels at
268 the baseline and age as predictors, showed that only age was the independent predictor of *Plasmodium*
269 parasite densities in the study population (coef= -0.02, P= 0.0004 for age; coef= 0.01, P= 0.9170 for

270 ME; coef= -0.19, P = 0.1529 for SE; coef= -0.02, P= 0.4746 for EBA-175; coef= 0.02, P= 0.5362 for
271 MSP-1_{19}).

272 Median IgG levels were not significantly different between participants with sub-microscopic
273 parasitemia and those with microscopic parasites at baseline (**Supplementary Figure 2A**), and no
274 significant difference was observed in the *in vitro* growth inhibition potential of inactivated plasma
275 from submicroscopic parasite carriers and that of microscopic carriers (**Supplementary Figure 2B**).
276 Both IgG antibody avidity (**Supplementary Figure 3A&B**) and growth inhibition potentials
277 (**Supplementary Figure 2B**) were similar in the two groups (P> 0.05). Together, these findings
278 suggest that anti-parasite antibodies may control parasite density levels by mechanisms other than
279 direct inhibition of parasite growth *in vivo*.

280



Figure 1. Older individuals (>20 years) had a better control of parasite densities. A) Scatterplot showing a correlation between baseline parasite densities and age in all the infected individuals with parasitemia at the detection limit of light microscopy (n= 138). Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-value (p), are shown. The red straight line was used to divide the study population into two groups aged ≤ 20 years and > 20 years old for further analyses. **B**) Scatterplot of correlation between baseline parasitemia detected by microscopy and age in different age groups (≤ 20 years and > 20 years) at the different time points of our study. Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-value (p), are shown for each age group. **C**) The pie chart shows the proportion of sub-microscopic infections (PCR+/microscopy-) versus microscopic (microscopy+) infections in each age group. PCR: Polymerase Chain Reaction.



Figure 2. Individuals >20 years old had more anti-parasite IgG at baseline. A) Data presented in the scatterplot represent baseline IgG antibody levels against different *P. falciparum* antigens (ME, SE, EBA-175 and MSP-1_{19}) within age groups. Median levels between age groups were compared by Wilcoxon signed-rank test and the p-values are shown on the graph. **B**) The scatterplots on B show the correlation between IgG levels against different *P. falciparum* antigens (ME, SE, EBA-175 and MSP-1_{19}) and age in different age groups (≤ 20 years and > 20 years). Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-values (p), are shown for each age group. SE: Schizont extract. ME: Merozoite extract. EBA-175: Erythrocyte binding antigen-175. MSP-1_{19}: Merozoite surface protein-1_{19}. OD: optical density.

308 Similarly, no significant difference was observed in malarial IgG antibody levels and avidity between
309 participants with symptomatic or asymptomatic parasitemia (**Supplementary Figure 4A**), and no
310 significant difference was seen in the blood parasitemia at the detection limit of microscopy
311 (Supplemental Figure 4B; **Table 1**). However, the *in vitro* growth inhibition potential of plasma from
312 asymptomatic malaria was greater than that of symptomatic individuals (P= 0.0245) despite no
313 significant differences in the parasitemia amongst those with parasite levels that were detectable by
314 microscopy (**Supplementary Figure 4B**). This may be a reflection of higher percentage of
315 asymptomatic children with submicroscopic parasitemias (77.7%) compared to symptomatic children
316 (90.5%) (**Supplementary Figure 4C**). Taken together, these data suggest that humoral responses
317 other than IgG responses to the tested parasite antigens contribute to the maintenance of
318 asymptomatic parasitemia in the study area.

319 **Persistence of fluctuating asymptomatic parasitemia occurred in highly exposed individuals**
320 **without alteration in IgG levels**

321 Of the 142 participants who completed the follow-up study as designed, 72 (50.7%) remained
322 asymptomatic during the 10-weeks follow-up period, whereas 69 (48.6%) developed malaria-
323 associated fevers and 1 (0.7%) resolved the infection in the absence of any known antimalarial
324 treatment. Surprisingly, the propensity to convert was not associated with age (**Figure 3A)**. Of the 72
325 participants who maintained chronic asymptomatic *P. falciparum* carriage, the proportion of
326 submicroscopic infections remained similar in both age groups with most participants becoming
327 microscopy positive on week 10 regardless of age (**Figure 3B**). Parasite densities fluctuated widely
328 over the follow-up period from ultra-low parasitemia (sub-microscopic) to high parasitemia (**Figure**
329 **3B**), possibly due to variation in the infecting clones from new infections as this is a high transmission
330 area (**Figure 3C**). However, no changes in IgG levels (**Figure 3D**) against all antigens tested were
331 observed during persistent asymptomatic infections indicating that persistent asymptomatic
332 parasitemia does not affect anti-*Plasmodium* IgG levels over this short 3-month time period. These

data suggests that asymptomatic carriage of *P. falciparum* occurs independently of circulating parasite numbers, even within highly-exposed individuals.



Figure 3. Asymptomatic malaria persisted in some individuals despite changes in the circulating parasite densities and population over time, but did not affect the antibody levels. **A**) The pie charts show the proportion of individuals with initial asymptomatic infection (cross-sectional) who resolved the infection (clearers), developed malaria-associated fever (uncomplicated malaria) or remained asymptomatic (persistent asymptomatic) over the 10-week follow-up period, according to age groups. **B**) Panel B displays the proportion of sub-microscopic/microscopic parasitemia in persistent asymptomatically infected individuals at three different time points (weeks 1, 4 and 11) according to age groups. Individuals who were RDT positive but without detectable micoroscopic parasitemia was detected are shown in pink. Of those who

had microscopic parasitemia, the line plots parasitemia across the 3 time points (**C**). To generate the line plots, the value 10 was assigned to submicroscopic parasitemia. The P values on the line plots refer to the comparison of the median parasitemia between two time points using the Wilcoxon test. **D**) Pie charts show the proportion of msp2 alleles (representing the clones) determined by nested PCR in individuals with persistent asymptomatic infection per week. Numbers represent the band sizes obtained. Blue slices represent the alleles only present at week 1. Red slices represent the alleles which appear at week4. Green slices represent the allele only present at week 11. Grey slices represent the alleles that were present at all three sampling time points (bands of 375, 400, 475, 500, 520, 534, 540, 600, 620, 633. 680, 700, 800 bp). **E**) Data presented in the line plots represent the profile of IgG anti-*Plasmodium* antibody levels in each chronic asymptomatically infected individuals at three different time points (week 1, 4 and 11) in the two age groups. SE: Schizont extract. ME: Merozoite extract. EBA-175: Erythrocyte binding antigen-175. MSP-1_{19}: Merozoite surface protein-1_{19}. OD: optical density.

Parasite density was associated with inflammatory responses amongst younger individuals with asymptomatic malaria

Given that *Plasmodium* parasites are associated with induction of inflammatory responses we measured the cytokine profiles of the 72 participants who had persistent asymptomatic carriage of *P. falciparum* across the course of our study. There was no particular cytokine signature that associated with asymptomatic carriage of *P. falciparum* in our study participants over the 11-week follow-up period (**Figure 4A**). Using a factor analysis of mixed data (FAMD) on cytokine data along with age and circulating parasite density, we found that levels of IL-10, TNF-α, the ratio of IL-10:IFN-γ and MCP-1, along with age and parasite density explained most of the variation in the peripheral cytokine response in asymptomatic individuals (**Figure 4B**). Multivariable analysis using age and parasitemia as predictors showed that age independently predicted the levels of TNF-α (coef= -0.31, P< 0.0001) peaking in younger study participants (**Figure 4C**). This is likely a reflection of circulating parasite densities which were higher in the younger group (**Figure 1**) and were also independently predictive of TNF-α levels (coef= 0.09, P< 0.0001) (**Figure 4D**). Circulating parasite density also independently predicted the levels of IL-10 (coef= 0.21, P< 0.0001) and MCP-1 (coef= 0.06, P= 0.01) with a significant increase in those who had high levels of parasitemia (parasitemia> 413.1 parasites/µl) relative to those who had low levels of microscopic parasitemia (parasitemia between 37.2 parasites/µl and 413.1 parasites/µl) (**Figure 4D**). This indicates that during asymptomatic carriage of *P. falciparum* circulating parasites simultaneously induce anti-inflammatory cytokine production to counteract the inflammatory effects of TNF-α. To determine which cytokines were dependent on parasite carriage we treated participants at week 11 of the study with ACT. This resulted in a significant decline in the IL-10 levels, but not TNF-α or MCP-1 levels, in the younger age group (**Figure 5**). Thus, the levels of IL-10 measured is a reflection of parasite carriage in the younger age group.



Figure 4. Cytokine responses were blunted with increased age and correlated with parasite densities at baseline. A) Hierarchical clustering of the standardized least-square means of 38 differentially expressed cytokines/chemokines/growth factors across the three sampling time points in participants with persistent asymptomatic infection (n= 72). **B**) Principal component of cytokines, age and parasitemia from FAMD (left graph) analysis. The right graph of B shows the contribution of each variable on the principal component 2 (dimension 2). **C** and **D)** box plots representing interquartile ranges (25th, median and 75th percentile, whisker

percentile (1st and 99th)) of the levels (Log10 pg/ml) of some main regulatory cytokines measured by Luminex according to age and parasite level groups at the baseline, respectively. Median levels of cytokines between two or more groups were compared by Wilcoxon rank-sum test and Kruskal-Wallis test, respectively. In Panel A, pairwise comparisons on neighboring groups were performed only when multiple comparisons were significant at $p< 0.05$. Parasite densities were groups in three groups as follows: submicroscopic parasitemia, low levels of microscopic parasitemia (parasitemia ≤ 413.1 parasites/µl, representing the median parasitemia in the study population) and high levels of parasitemia (parasitemia> 413.1 parasites/µl). FAMD: Factor analysis of mixed data. *$p< 0.05$; **$p< 0.001$, ***$p< 0.0001$, ****$p< 0.00001$.



Figure 5. IL-10 and TNF-α levels were a reflection of parasite carriage, and the balance of inflammatory cytokines at baseline was associated with the maintenance of asymptomatic infections in the younger age, ≤ 20 years. A) Box plots representing interquartile ranges (25th, median and 75th percentile, whisker percentile (1st and 99th)) of cytokine levels (Log_{10} pg/ml) during persistent asymptomatic infections (week 1, 4 and 11) and after anti-malarial treatment (week 16). **B**) Box plots representing interquartile ranges (25th, median and 75th percentile, whisker percentile (1st and 99th)) of cytokine levels (Log_{10} pg/ml) at the baseline between in those who developed uncomplicated malaria (UM; grey) and those who went on to display persistent asymptomatic malaria throughout the course of the study (PAM; blue). Analyses were performed including values from individuals with submicroscopic and microscopic parasitemia. Median cytokines levels between two or more groups were compared by Wilcoxon rank-sum test and Kruskal-Wallis test, respectively and significant between group differences indicated by the P value on the plot. In Panel A, pairwise comparisons on neighboring groups were performed only when multiple comparisons between the 4 groups were significant and are shown by the grey brackets. *p< 0.05 and ***p< 0.0001.

413 **Maintenance of asymptomatic carriage of *P. falciparum* is associated with a more balanced**
414 **inflammatory cytokine ratio**

415 There was no particular cytokine signature of asymptomatic individuals relative to symptomatic
416 individuals in our study (**Figure 6A**). However, given that anti-inflammatory cytokines may be
417 important in down-regulating the pathogenic inflammatory response in malaria, we tested the
418 hypothesis that asymptomatic infection would be associated with higher levels of IL-10. To our
419 surprise, at the initial time point of our study there was a non-significant trend towards higher levels
420 of IL-10 in the symptomatic compared to asymptomatic participants (**Figure 6B**). This may be a
421 reflection of higher inflammation levels in symptomatic individuals as other pro-inflammatory
422 markers (IL-6 and MCP-1) were significantly higher in individuals with symptomatic malaria
423 compared to those with asymptomatic *P. falciparum* infections in the younger age group (**Figure 6B**).
424 There was an IL-10-skewed ratio of IL-10:TNF-α and IL-10:IFN-γ in the symptomatic group
425 compared to the asymptomatic group in both age groups (**Figure 6C**). This is in agreement with
426 previously published data in individuals with uncomplicated malaria and the IL-10 skewed ratio of
427 IL-10 to TNF-α that can be measured in those with severe symptoms of malaria [38,39].
428 Multivariable logistic regression analysis showed that the IL-10:TNF-α ratio and IL-1RA levels were
429 independently associated with developing symptoms during *P. falciparum* infection in this study
430 (**Supplementary Table S1**).

431

432



Figure 6. IL-10 at baseline was associated with clinical malaria in the younger age group (≤ 20 years). A) Hierarchical clustering (heatmap) of the standardized least-square means of 38 differentially expressed cytokines/chemokines/growth factors by infection status at the baseline of this study. **B** and **C** box plots represent interquartile ranges (25th, median and 75th percentile, whisker percentile (1st and 99th)) of the baseline cytokine levels (Log_{10} pg/ml) measured by Luminex according to infection status. Analyses were performed including both individuals submicroscopic and microscopic parasitemia. Median levels of cytokines between two or three groups were compared by Wilcoxon rank-sum test and Kruskal-Wallis test, respectively.

In Panel B and C, pairwise comparisons were performed only when multiple comparisons were significant. P values refer to the Kruskal-Wallis test comparison between the three groups. NI: Non-infected. AS: Asymptomatic. SY: Symptomatic. *p< 0.05; **p< 0.001; ***p< 0.0001.

To further test the hypothesis that asymptomatic carriage of *P. falciparum* may be related to IL-10 production, we compared the cytokine ratios in the younger group who converted to symptomatic malaria throughout our study with those who remained asymptomatic. At the initial time point of the study there was a trend towards increased IL-10 levels in those who subsequently went on to develop uncomplicated malaria compared to those who experienced persistent asymptomatic malaria in both age groups. In the younger age group IL-10/pro-inflammatory cytokine ratios were significantly higher and IL-10-skewed (P= 0.0207 and P= 0.0111 for IL-10:TNF-α and IL-10:IFN-γ ratios, respectively) in the those developing uncomplicated malaria compared to those with persistent asymptomatic malaria in younger age group (**Figure 5B**). In this group those with persistent asymptomatic malaria had a ratios of 1.001±0.1355 for IL-10:TNF-α and 1.016±0.1794 for IL-10:IFN-γ) displaying an even balance of IL-10: proinflammatory cytokine. On the other hand adults did not have IL-10 skewed ratios with TNF-α or IFN-γ suggesting that a different or additional mechanism may facilitate the persistence of asymptomatic malaria in the older age group. Collectively this data suggests that IL-10 is not sufficient to dampen inflammatory responses in *Plasmodium* infection that lead to the fevers that define uncomplicated malaria.

Discussion

Significant gaps exist in the understanding of the contribution of anti-parasite and anti-disease immunity in the persistent asymptomatic parasite carriage in areas with high transmission of *P. falciparum*. Mathematical modelling of existing data indicates that asymptomatic *P. falciparum* infections could last for as long as 13-years [40] and field data documents the longevity of asymptomatic infections ranges from at least 2-9 months [7,41,42]. As we have previously

467 published, our study area has high rate of persistent asymptomatic parasite carriage over the 3 month
468 time period of study [24]. However, a proportion of individuals in our study converted to symptomatic
469 malaria as defined by the development of fever. Thus, we have assessed immune correlates of
470 asymptomatic carriage of *P. falciparum*, as well as the predictors of conversion to symptomatic
471 malaria.

472 Consistent with the acquisition of immune response with age and exposure [13,43] in our study, older
473 asymptomatic individuals had better control of circulating iRBCs with a greater proportion of sub-
474 microscopic infections than younger individuals. This was associated with an increase in the quantity
475 of circulating anti-parasite IgG which appeared to saturate at around 20 years old. Our data is in
476 agreement with an age-structured mathematical model of malaria transmission which showed that
477 anti-parasite immunity which results in more rapid clearance of parasitemia has an approximate half-
478 life of 20 years [44]. With a focus on the younger age group, there did not appear to be any correlations
479 with respect to parasitemia levels and IgG levels or the avidity of the IgG. The *in vitro* invasion-
480 blocking capability of the plasma in young individuals had some functionality with respect to invasion
481 blocking, but only at higher parasitemia levels. In this assay plasma factors other than IgG, such as
482 IgM [45,46], may contribute to this observation and control of *P. falciparum* parasitemia in children.
483 Collectively these data support a role for IgG in exerting control of iRBCs in *P. falciparum* infections,
484 but it may not be the principal factor that dictates asymptomatic carriage of parasites in younger
485 individuals.

486 Surprisingly the proportion of those developing uncomplicated malaria over the course of our study
487 was comparable between the younger and the older age groups, suggesting that the conversion from
488 an asymptomatic to symptomatic infection is independent of age in highly exposed individuals. The
489 reasons for this finding are not clear but may be related to heterogeneity of the circulating *P.*
490 *falciparum* parasite population and emergence of highly inflammatory parasite clonotypes [47,48]
491 that overcome the pyrogenic threshold of individuals. Consistent with the oscillation of parasite
492 densities over time reported in a Vietnam cohort [7], parasitemia in persistent asymptomatic

493 infections in our study fluctuated widely and independently of IgG levels, and different clonotypes
494 of *P. falciparum* were observed at different time points in this study.

495 Cytokine profiles are considerably more dynamic than IgG responses. In line with the hypothesis that
496 clinical immunity to malaria is mediated by a tempering of inflammation, previous studies have
497 shown that the clinical outcome of malaria infection is largely dictated by the balance between pro-
498 inflammatory and anti-inflammatory markers [17,18]. Although our study highlighted that carriage
499 of *P. falciparum* across the duration of this study was associated with a consistent inflammatory
500 response characterized by TNF-α, IL-10 and MCP-1, we found no obvious cytokine signature
501 associated with the asymptomatic carriage of *P. falciparum* when compared to symptomatic
502 individuals. Similar to findings in a study of visceral leishmaniasis [49], where increased IL-10 levels
503 were the primary predictor of clinical conversion from asymptomatic to symptomatic
504 visceral leishmaniasis, the conversion from asymptomatic to symptomatic malaria in our study was
505 linked to increased baseline levels of IL-10 skewed ratios with TNF-α and IFN-γ in children at the
506 initial time point of our study.

507 Although IL-10 is known to exert anti-inflammatory effects that include inhibition of monocytes and
508 macrophages in the production of inflammatory cytokines such as IL-6, TNF-α, and IL-l [50], in
509 agreement with a recent study from the Gambia [51] in our study IL-10 was associated with the
510 presence of *Plasmodium* parasites. Given that higher levels of IL-6, IL-1RA and MCP-1 were also
511 associated with symptomatic infections in the younger age group of our study, IL-10 levels are likely
512 a consequence of increased inflammation. Notably, IL-10 induces IL1RA, a potent anti-inflammatory
513 cytokine that regulates the pro-inflammatory actions of IL-1 [52] that has previously been shown to
514 be associated with severity of malarial disease [53]. At the baseline time point in our study, we found
515 that balanced inflammatory cytokine ratios were correlated with developing symptoms from *P.*
516 *falciparum* infection in our younger age group. Specifically, those who developed uncomplicated
517 malaria had a significant IL-10 skewed ratio at the initial time point compared to those who had

518 persistent asymptomatic malaria. An IL-10 skewed ratio may indicate that an individual will shortly
519 develop symptoms of *P. falciparum* infection.

520 Most of the association between biomarkers and clinical malaria in this study were only found in the
521 younger age group, but not in adults, indicating that the mechanisms of the protection against clinical
522 malaria may be different according to age. As such, more studies into how asymptomatic carriage of
523 *Plasmodium* occurs are warranted and should include non-antibody mediated mechanisms of parasite
524 control and clinical immunity which may be relevant in children.
525

526 **Acknowledgements**

527 We thank the field staff and, most importantly, residents of the Esse Health district in Cameroon who
528 participated in this study.

529

530 **Author contributions**

531 BF devised the experiments, performed the experiments, analyzed data, and wrote the paper; FM,
532 MFA, EE, CD, GC, MK, RK and SK performed fieldwork and sample processing; MS and RP
533 provided cytokine kits and recombinant *P. falciparum* antigens, respectively and reviewed paper. RM
534 supervised the experiments and reviewed paper; LA and TL devised the experiments, supervised the
535 experiments, analyzed data, and wrote the paper.

536 **Financial Support:**

537 This work was supported by the Institute Pasteur International Division to LSA.

538 **Competing interests**

539 Authors declare no competing interests.
540

541 **References**

542 1. WHO. World Malaria Report. Genova; 2023.

543 2. Cibulskis RE, Alonso P, Aponte J, et al. Malaria: Global progress 2000 - 2015 and future
544 challenges. Infect Dis Poverty. **2016**; 5(1):61.

545 3. Galatas B, Bassat Q, Mayor A. Malaria Parasites in the Asymptomatic: Looking for the Hay in
546 the Haystack. Trends Parasitol. **2016**; 32(4):296–308.

547 4. Drakeley C, Gonçalves B, Okell L, Slater H. Understanding the Importance of Asymptomatic
548 and Low- Density Infections for Malaria Elimination. In: Manguin S, Dev V, editors. Malar
549 Elimin - Leap Forw [Internet]. InTech; 2018 [cited 2018 Sep 4]. Available from:
550 http://www.intechopen.com/books/towards-malaria-elimination-a-leap-
551 forward/understanding-the-importance-of-asymptomatic-and-low-density-infections-for-
552 malaria-elimination

553 5. Ashley EA, White NJ. The duration of Plasmodium falciparum infections. Malar J. **2014**;
554 13(1):500.

555 6. Slater HC, Ross A, Felger I, et al. The temporal dynamics and infectiousness of subpatent
556 Plasmodium falciparum infections in relation to parasite density. Nat Commun [Internet]. **2019**
557 [cited 2020 Jun 4]; 10. Available from:
558 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440965/

559 7. Nguyen T-N, Seidlein L von, Nguyen T-V, et al. The persistence and oscillations of
560 submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in
561 Vietnam: an open cohort study. Lancet Infect Dis. **2018**; 18(5):565–572.

562 8. Ademolue TW, Awandare GA. Evaluating antidisease immunity to malaria and implications for
563 vaccine design. Immunology. **2018**; 153(4):423–434.

564 9. Ademolue TW, Awandare GA. Evaluating antidisease immunity to malaria and implications for
565 vaccine design. Immunology. **2018**; 153(4):423–434.

566 10. Kijogi C, Kimura D, Bao LQ, et al. Modulation of immune responses by Plasmodium falciparum
567 infection in asymptomatic children living in the endemic region of Mbita, western Kenya.
568 Parasitol Int. **2018**; 67(3):284–293.

569 11. Ouédraogo M, Samadoulougou S, Rouamba T, et al. Spatial distribution and determinants of
570 asymptomatic malaria risk among children under 5 years in 24 districts in Burkina Faso. Malar
571 J. **2018**; 17:460.

572 12. Griffin JT, Hollingsworth TD, Reyburn H, Drakeley CJ, Riley EM, Ghani AC. Gradual
573 acquisition of immunity to severe malaria with increasing exposure. Proc R Soc B Biol Sci.
574 **2015**; 282(1801):20142657–20142657.

575 13. White M, Watson J. Age, exposure and immunity. eLife [Internet]. **2021** [cited 2021 Mar 31];
576 7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103766/

577 14. Boyle MJ, Reiling L, Feng G, et al. Human Antibodies Fix Complement to Inhibit Plasmodium
578 falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria.
579 Immunity. **2015**; 42(3):580–590.

580 15. Duncan CJA, Hill AVS, Ellis RD. Can growth inhibition assays (GIA) predict blood-stage
581 malaria vaccine efficacy? Hum Vaccines Immunother. **2012**; 8(6):706–714.

582 16. Garcia-Senosiain A, Kana IH, Singh S, et al. Neutrophils dominate in opsonic phagocytosis of
583 P. falciparum blood-stage merozoites and protect against febrile malaria. Commun Biol. **2021**;
584 4(1):984.

585 17. Rovira-Vallbona E, Moncunill G, Bassat Q, et al. Low antibodies against Plasmodium
586 falciparum and imbalanced pro-inflammatory cytokines are associated with severe malaria in
587 Mozambican children: a case–control study. Malar J. **2012**; 11:181.

588 18. Andrade BB, Santos CJN, Camargo LM, et al. Hepatitis B Infection Is Associated with
589 Asymptomatic Malaria in the Brazilian Amazon. PLOS ONE. **2011**; 6(5):e19841.

590 19. Kimenyi KM, Wamae K, Ochola-Oyier LI. Understanding P. falciparum Asymptomatic
591 Infections: A Proposition for a Transcriptomic Approach. Front Immunol [Internet]. **2019** [cited
592 2019 Dec 12]; 10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803459/

593 20. Guiyedi V, Bécavin C, Herbert F, et al. Asymptomatic Plasmodium falciparum infection in
594 children is associated with increased auto-antibody production, high IL-10 plasma levels and
595 antibodies to merozoite surface protein 3. Malar J [Internet]. **2015** [cited 2018 Feb 5]; 14(1).
596 Available from: http://www.malariajournal.com/content/14/1/162

597 21. Gonçalves RM, Scopel KK, Bastos MS, Ferreira MU. Cytokine balance in human malaria: does
598 Plasmodium vivax elicit more inflammatory responses than Plasmodium falciparum? PLoS
599 One. **2012**; 7(9):e44394.

600 22. Wilson NO, Bythwood T, Solomon W, et al. Elevated levels of IL-10 and G-CSF associated
601 with asymptomatic malaria in pregnant women. Infect Dis Obstet Gynecol. **2010**; 2010.

602 23. Essangui E, Moukoko CEE, Nguedia N, et al. Demographical, hematological and serological
603 risk factors for Plasmodium falciparum gametocyte carriage in a high stable transmission zone
604 in Cameroon. PLOS ONE. **2019**; 14(4):e0216133.

605 24. Fogang B, Biabi MF, Megnekou R, et al. High Prevalence of Asymptomatic Malarial Anemia
606 and Association with Early Conversion from Asymptomatic to Symptomatic Infection in a
607 Plasmodium falciparum Hyperendemic Setting in Cameroon. Am J Trop Med Hyg. **2021**;
608 :tpmd210316.

609 25. Biabi MFAB, Fogang B, Essangui E, et al. High Prevalence of Polyclonal Plasmodium
610 falciparum Infections and Association with Poor IgG Antibody Responses in a Hyper-Endemic
611 Area in Cameroon. Trop Med Infect Dis. **2023**; 8(8):390.

612 26. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil
613 resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase
614 chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. **1995**; 52(6):565–568.

615 27. Ranford-Cartwright LC, Taylor J, Umasunthar T, et al. Molecular analysis of recrudescent
616 parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg.
617 **1997**; 91(6):719–724.

618 28. Quintana M del P, Ch'ng J-H, Zandian A, et al. SURGE complex of Plasmodium falciparum in
619 the rhoptry-neck (SURFIN4.2-RON4-GLURP) contributes to merozoite invasion. PLOS ONE.
620 **2018**; 13(8):e0201669.

621 29. Heiber A, Spielmann T. Preparation of parasite protein extracts and western blot analysis. Bio-
622 Protoc. **2014**; 4:e1136.

623 30. Bonnet S, Pêtres S, Holm I, et al. Soluble and glyco-lipid modified baculovirus Plasmodium
624 falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine
625 candidate. Vaccine. **2006**; 24(33–34):5997–6008.

626 31. Perraut R, Varela M-L, Loucoubar C, et al. Serological signatures of declining exposure
627 following intensification of integrated malaria control in two rural Senegalese communities.
628 PLoS ONE [Internet]. **2017** [cited 2019 Sep 8]; 12(6). Available from:
629 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469466/

630 32. Berry AA, Gottlieb ER, Kouriba B, et al. Immunoglobulin G subclass and antibody avidity
631 responses in Malian children immunized with Plasmodium falciparum apical membrane antigen
632 1 vaccine candidate FMP2.1/AS02 A. Malar J. **2019**; 18(1):13.

633 33. Duncan EH, Bergmann-Leitner ES. Miniaturized Growth Inhibition Assay to Assess the Anti-
634 blood Stage Activity of Antibodies. In: Vaughan A, editor. Malar Vaccines [Internet]. New
635 York, NY: Springer New York; 2015 [cited 2019 Apr 30]. p. 153–165. Available from:
636 http://link.springer.com/10.1007/978-1-4939-2815-6_13

637 34. Efange NM, Lobe MMM, Keumoe R, Ayong L, Efange SMN. Spirofused
638 tetrahydroisoquinoline-oxindole hybrids as a novel class of fast acting antimalarial agents with
639 multiple modes of action. Sci Rep. **2020**; 10:17932.

640 35. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. R
641 Foundation for Statistical Computing; 2021. Available from: https://www.R-project.org/

642 36. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J
643 Stat Softw. 2015;67(1):1-48.
644
645 37. Kuznetsova A, Brockhoff P, Christensen R. lmerTest: Tests in linear mixed effects models.
646 https://cranr-projectorg/package=lmerTest. 2016.
647
648 38. May J, Lell B, Luty AJ, Meyer CG, Kremsner PG. Plasma interleukin-10:Tumor necrosis factor
649 (TNF)-alpha ratio is associated with TNF promoter variants and predicts malarial complications.
650 J Infect Dis. **2000**; 182(5):1570–1573.

651 39. Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V. A low interleukin-10
652 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a
653 holoendemic malaria region in western Kenya. J Infect Dis. 1999;179(1):279-82. doi:
654 10.1086/314548. PubMed PMID: 9841855.

655 40. Ashley EA, White NJ. The duration of Plasmodium falciparum infections. Malar J. **2014**;
656 13(1):500.

657 41. Felger I, Maire M, Bretscher MT, et al. The Dynamics of Natural Plasmodium falciparum
658 Infections. Gosling RD, editor. PLoS ONE. **2012**; 7(9):e45542.

659 42. Landier J, Kajeechiwa L, Thwin MM, et al. Safety and effectiveness of mass drug administration
660 to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages
661 of Eastern Myanmar. Wellcome Open Res. **2017**; 2:81.

662 43. Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, et al. Quantification of anti-parasite and
663 anti-disease immunity to malaria as a function of age and exposure. eLife. **2018**; 7:e35832.

664 44. Filipe JAN, Riley EM, Drakeley CJ, Sutherland CJ, Ghani AC. Determination of the Processes
665 Driving the Acquisition of Immunity to Malaria Using a Mathematical Transmission Model.
666 PLOS Comput Biol. Public Library of Science; **2007**; 3(12):e255.

667 45. Hopp CS, Sekar P, Diouf A, et al. Plasmodium falciparum-specific IgM B cells dominate in
668 children, expand with malaria, and produce functional IgM. J Exp Med. **2021**;
669 218(4):e20200901.

670 46. Thouvenel CD, Fontana MF, Netland J, et al. Multimeric antibodies from antigen-specific
671 human IgM+ memory B cells restrict Plasmodium parasites. J Exp Med. **2021**;
672 218(4):e20200942.

673 47. Corrigan RA, Rowe JA. Strain variation in early innate cytokine induction by Plasmodium
674 falciparum. Parasite Immunol. **2010**; 32(7):512–527.

675 48. Allan RJ, Rowe A, Kwiatkowski D. Plasmodium falciparum varies in its ability to induce tumor
676 necrosis factor. Infect Immun. **1993**; 61(11):4772–4776.

677 49. Topno RK, Kumar R, Pandey K, et al. Early diagnostic marker for the conversion of
678 asymptomatic to symptomatic visceral leishmaniasis. J Med Allied Sci. **2019**; 9(2):96–99.

679 50. Waal Malefyt R de, Abrams J, Bennett B, Figdor CG, Vries JE de. Interleukin 10(IL-10) inhibits
680 cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by
681 monocytes. J Exp Med. **1991**; 174(5):1209–1220.

682 51. Mooney JP, DonVito SM, Jahateh M, et al. "Bouncing Back" From Subclinical Malaria:
683 Inflammation and Erythrocytosis After Resolution of P. falciparum Infection in Gambian
684 Children. Front Immunol. **2022**; 13:780525.

685 52. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in
686 biology. Annu Rev Immunol. **1998**; 16:27–55.

687 53. John CC, Park GS, Sam-Agudu N, Opoka RO, Boivin MJ. Elevated serum levels of IL-1ra in
688 children with P. falciparum malaria are associated with increased severity of disease. Cytokine.
689 **2008**; 41(3):204–208.

690

691